Connect with us

Technology

Agility Opens New Fremont Facility to Accelerate Physical AI Development

Published

2 months ago

on

Bay Area facility will advance the AI technologies that enable its humanoid robot, Digit, to learn new skills, supporting expanded capabilities across commercial deployments.

FREMONT, Calif., July 16, 2026 /PRNewswire/ — Agility, a leading humanoid robotics and Physical AI company, today announced the opening of its new Fremont, California, facility designed to accelerate Physical AI developments that directly improve performance in customer operations. The new site will serve as the company’s software and capabilities hub, where engineering teams will train, test and advance the AI technologies that enable Agility’s humanoid, Digit, to learn new skills and perform more sophisticated tasks in customer environments.

The 60,000-square-foot facility complements Agility’s RoboFab manufacturing operations in Salem, Oregon, establishing Agility’s Bay Area Physical AI development hub in the heart of Silicon Valley.

Agility will house nearly 200 existing and new employees including hardware engineering, AI/ML software engineering, and field operations to lead development and deployment of next-generation AI capabilities to extend Digit’s market lead in safety and productivity in enterprise environments.

“Being in the heart of Silicon Valley brings us into one of the world’s leading AI talent and innovation ecosystems, allowing us to develop new capabilities for Digit faster and put them to work for customers immediately,” said Peggy Johnson, CEO of Agility. “Being one of the only companies operationally deploying humanoids in real enterprise environments, our Fremont facility will play a critical role in driving innovation that anticipates and delivers on the capabilities our customers need.”

Agility has active humanoid deployments with Schaeffler, GXO, Toyota Motor Manufacturing Canada, and Mercado Libre. The company has already secured more than $300 million of multi-year orders for Digit v5, subject to the realization of certain contractual milestones and a growing pipeline of over 30 customers, reflecting growing demand from enterprises preparing to deploy humanoid robots at scale. The Fremont facility is vital to meet this demand and spark even greater uptake by delivering ongoing safety and productivity advantages built on AI that can increasingly take on more repetitive, physically demanding tasks in warehouses and manufacturing facilities while working safely alongside people.

“Fremont is where the future is built. Agility Robotics’ decision to establish its AI development hub here reflects the strength of our talent, our culture of innovation, and our leadership in advanced manufacturing and robotics,” said Fremont Mayor Raj Salwan. “We’re proud to welcome Agility to our community, along with nearly 200 high-quality jobs and continued investment in Fremont.”

Agility is expanding its physical footprint ahead of its planned public listing via business combination with Churchill Capital Corp XI (NASDAQ: CCXI), whereby the company will become the first publicly listed U.S. pure-play humanoid robotics company.

About Agility Robotics

Agility’s commercially deployed humanoids operate alongside teams in warehouses, manufacturing facilities and distribution centers – tackling physically demanding and repetitive tasks while enabling workers to focus on higher-value work. With industry-leading safety standards and years of proven deployment data, we’re pioneering a new era of automation that enhances human potential. To learn more, visit agilityrobotics.com.

About Churchill Capital Corp XI

Churchill XI is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It may pursue an initial business combination target in any business or industry.

Additional Information About the Proposed Transaction and Where to Find It
The proposed transaction will be submitted to shareholders of Churchill XI for their consideration. Churchill XI intends to file a registration statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission (“SEC”), which will include preliminary and definitive proxy statements to be distributed to Churchill XI’s shareholders in connection with Churchill XI’s solicitation of proxies for the vote by Churchill XI’s shareholders in connection with the proposed transaction and other matters to be described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Company stockholders in connection with the completion of the proposed transaction. After the Registration Statement has been filed and declared effective, a definitive proxy statement/prospectus and other relevant documents will be mailed to Churchill XI shareholders as of the record date established for voting on the proposed transaction. Before making any voting or investment decision, Churchill XI and Company stockholders and other interested persons are advised to read, once available, the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus statement, as well as other documents filed with the SEC by Churchill XI in connection with the proposed transaction, as these documents will contain important information about Churchill XI, the Company and the proposed transaction. Shareholders may obtain a copy of the preliminary or definitive proxy statement/prospectus statement, once available, as well as other documents filed by Churchill XI with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to Churchill XI Capital Corp XI, 640 Fifth Avenue, 14th Floor, New York, NY 10019.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. We have based these forward-looking statements on current expectations and projections about future events. These statements include statements relating to, without limitation: our ability to consummate the proposed business combination and PIPE and the satisfaction or waiver of the closing conditions set forth in the proposed business combination or PIPE subscription agreements; the occurrence of any other event, change or other circumstances that could give rise to the termination of the proposed business combination or PIPE subscription agreements; projections of market opportunity and market share; estimates of customer adoption rates, market acceptance and usage patterns; projections regarding the Company’s future development plans; the timing and success of the Company’s future development plans; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products and services; the potential for share price appreciation; the expected timing of announcement and close of the potential transaction; the Company’s economic opportunity and total addressable market; the expected amount of gross transaction proceeds and the planned pre-money valuation of the Company; expectations regarding the Company’s ability to attract, retain and expand its customer base; the Company’s deployment of proceeds from capital raising transaction; the Company’s expectations concerning relationships with strategic partners, suppliers, regulatory bodies and other third parties; the Company’s ability to maintain, protect and enhance its intellectual property; future ventures or investments in companies, products, services or technologies; development of favorable regulations affecting the Company’s markets; the potential benefits of the proposed transaction and expectations related to its terms and timing; and the potential for the combined company to increase in value.

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions, many of which are beyond the control of the Company and Churchill XI.

These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause Churchill XI’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such statements. Such risks and uncertainties include: that the Company is pursuing an emerging technology, faces significant technical challenges and may not achieve commercialization or market acceptance; the Company’s historical net losses and limited operating history; the Company’s expectations regarding future financial performance, capital requirements and unit economics; the Company’s use and reporting of business and operational metrics; the Company’s competitive landscape; the Company’s dependence on members of its senior management and its ability to attract and retain qualified personnel; the potential need for additional future financing; the Company’s ability to manage growth and expand its operations; potential future acquisitions or investments in companies, products, services or technologies; the Company’s reliance on strategic partners and other third parties; the Company’s ability to maintain, protect and defend its intellectual property rights; risks associated with privacy, data protection or cybersecurity incidents and related regulations; the use, rate of adoption and regulation of artificial intelligence and machine learning; uncertainty or changes with respect to laws and regulations; uncertainty or changes with respect to taxes, trade conditions and the macroeconomic environment; the combined company’s ability to maintain internal control over financial reporting and operate a public company; the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of Churchill XI’s securities; the failure by the parties to satisfy the conditions to consummation of the proposed transaction, including the approval of Churchill XI’s shareholders; the possibility that required regulatory approvals for the proposed transaction are delayed or are not obtained, which could adversely affect the combined company or the expected benefits of the proposed transaction; the risk that shareholders of Churchill XI could elect to have their shares redeemed, leaving the combined company with insufficient cash to execute its business plans; the level of redemptions of Churchill XI’s public shareholders; the ability of the Company to grow and manage growth, maintain relationships with customers and retain its management and key employees; costs related to the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the outcome of any legal proceedings or government investigations that may be commenced against the Company or Churchill XI; failure to realize the anticipated benefits of the proposed transaction; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of Churchill XI or the combined company to issue equity or equity-linked securities in connection with the proposed transaction or in the future; and other factors described in Churchill XI’s filings with the SEC. Additional information concerning these and other factors that may impact such forward-looking statements can be found in filings and potential filings by the Company, Churchill XI or the combined company resulting from the proposed transaction with the SEC, including under the heading “Risk Factors.” If any of these risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, these statements reflect the expectations, plans and forecasts of the Company’s and Churchill XI’s management as of the date of this press release; subsequent events and developments may cause their assessments to change. While the Company and Churchill XI may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so. Accordingly, undue reliance should not be placed upon these statements.

In addition, statements that “we believe” and similar statements reflect Churchill XI’s beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and Churchill XI’s statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

An investment in Churchill XI is not an investment in any of Churchill XI’s founders’ or sponsors’ past investments, companies or affiliated funds. The historical results of those investments are not indicative of future performance of Churchill XI, which may differ materially from the performance of Churchill XI’s founders’ or sponsors’ past investments.

Participants in the Solicitation

Churchill XI, the Company and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from Churchill XI’s shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Churchill XI’s shareholders in connection with the proposed transaction will be set forth in proxy statement/prospectus statement when it is filed by Churchill XI with the SEC. You can find more information about Churchill XI’s directors and executive officers in Churchill XI’s final prospectus related to its initial public offering filed with the SEC on December 16, 2025. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus statement when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus statement carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources described above.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This press release is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

View original content to download multimedia:https://www.prnewswire.com/news-releases/agility-opens-new-fremont-facility-to-accelerate-physical-ai-development-302827927.html

SOURCE Agility

Related Topics:
Continue Reading

Technology

DR. PHONE FIX ANNOUNCES CLOSING OF NON-BROKERED CONVERTIBLE DEBENTURE UNIT FINANCING

Published

55 minutes ago

on

September 25, 2026

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

EDMONTON, AB, Sept. 25, 2026 /CNW/ — Dr. Phone Fix Canada Corporation (“Dr. Phone Fix” or the “Company”) (TSXV: DPF) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) of convertible debenture units of the Company (each, a “Unit”). The Company issued an aggregate of 1,608 Units, at a price of $1,000 per Unit, for aggregate gross proceeds of $1,608,000. Each Unit is comprised of (i) one $1,000 principal amount unsecured convertible debenture of the Company (a “Convertible Debenture”) and (ii) 3,125 common share (“Common Share”) purchase warrants of the Company (each, a “Warrant”). Additional detail on the Offering, including terms of the Convertible Debentures and Warrants, is set out in the news release dated May 19, 2026.

In connection with the Offering, the Company paid a finder’s fee consisting of an aggregate cash fee of $110,810 and issued an aggregate of 692,562 common share purchase warrants of the Company (each, a “Finder’s Warrant”) to certain qualified arm’s length parties. Each Finder’s Warrant is exercisable to acquire one Common Share of the Company at an exercise price of $0.22 prior to the date that is 24 months from the date of issuance.

All securities issued pursuant to the Offering, including any Common Shares issuable upon conversion of the Convertible Debentures or exercise of the Warrants and Finder’s Warrants, are subject to a statutory hold period of four months and one day from the closing of the Offering, in accordance with applicable securities laws and TSX Venture Exchange (the “TSXV”) policies. 

The Offering remains subject to final acceptance of the TSXV.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Dr. Phone Fix

Dr. Phone Fix is Canada’s award-winning, eco-friendly integrated device care platform providing repair, refurbishment, certified pre-owned devices, trade-in solutions, accessories and related services through its growing national retail network. Founded in 2019, the Company serves consumers and businesses across multiple Canadian markets, delivering convenient and reliable device care solutions through its corporately owned retail network. With a focus on operational execution, customer service and sustainability, Dr. Phone Fix continues to expand its national platform while supporting the repair, reuse and extension of the useful life of connected devices.

www.docphonefix.com

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Forward-Looking Information and Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the final acceptance of the Offering by the TSXV; and the expected use of proceeds following the closing of the Offering. Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the Company’s financial condition and development plans do not change as a result of unforeseen events; the TSXV will provide its final acceptance of the Offering; and the Company will be able to obtain the financing required in order to develop and continue its business and operations. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to obtain TSXV final acceptance for the Offering; market conditions and investor demand for the Company’s securities on an ongoing basis; the Company’s inability to deploy the proceeds as currently intended; and general economic and market conditions. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE Dr. Phone Fix

Continue Reading

Technology

DR. PHONE FIX ANNOUNCES CLOSING OF NON-BROKERED CONVERTIBLE DEBENTURE UNIT FINANCING

Published

55 minutes ago

on

September 25, 2026

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

EDMONTON, AB, Sept. 25, 2026 /CNW/ — Dr. Phone Fix Canada Corporation (“Dr. Phone Fix” or the “Company”) (TSXV: DPF) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Offering”) of convertible debenture units of the Company (each, a “Unit”). The Company issued an aggregate of 1,608 Units, at a price of $1,000 per Unit, for aggregate gross proceeds of $1,608,000. Each Unit is comprised of (i) one $1,000 principal amount unsecured convertible debenture of the Company (a “Convertible Debenture”) and (ii) 3,125 common share (“Common Share”) purchase warrants of the Company (each, a “Warrant”). Additional detail on the Offering, including terms of the Convertible Debentures and Warrants, is set out in the news release dated May 19, 2026.

In connection with the Offering, the Company paid a finder’s fee consisting of an aggregate cash fee of $110,810 and issued an aggregate of 692,562 common share purchase warrants of the Company (each, a “Finder’s Warrant”) to certain qualified arm’s length parties. Each Finder’s Warrant is exercisable to acquire one Common Share of the Company at an exercise price of $0.22 prior to the date that is 24 months from the date of issuance.

All securities issued pursuant to the Offering, including any Common Shares issuable upon conversion of the Convertible Debentures or exercise of the Warrants and Finder’s Warrants, are subject to a statutory hold period of four months and one day from the closing of the Offering, in accordance with applicable securities laws and TSX Venture Exchange (the “TSXV”) policies. 

The Offering remains subject to final acceptance of the TSXV.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Dr. Phone Fix

Dr. Phone Fix is Canada’s award-winning, eco-friendly integrated device care platform providing repair, refurbishment, certified pre-owned devices, trade-in solutions, accessories and related services through its growing national retail network. Founded in 2019, the Company serves consumers and businesses across multiple Canadian markets, delivering convenient and reliable device care solutions through its corporately owned retail network. With a focus on operational execution, customer service and sustainability, Dr. Phone Fix continues to expand its national platform while supporting the repair, reuse and extension of the useful life of connected devices.

www.docphonefix.com

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Forward-Looking Information and Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the final acceptance of the Offering by the TSXV; and the expected use of proceeds following the closing of the Offering. Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the Company’s financial condition and development plans do not change as a result of unforeseen events; the TSXV will provide its final acceptance of the Offering; and the Company will be able to obtain the financing required in order to develop and continue its business and operations. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to obtain TSXV final acceptance for the Offering; market conditions and investor demand for the Company’s securities on an ongoing basis; the Company’s inability to deploy the proceeds as currently intended; and general economic and market conditions. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE Dr. Phone Fix

Continue Reading

Technology

AI in Clinical Trials Market to Reach USD 7.32 Billion by 2034 as AI Reshapes Patient Recruitment, Data Analysis and Drug Development, says Maximize Market Research

Published

55 minutes ago

on

September 25, 2026

By

PUNE, India, Sept. 25, 2026 /PRNewswire/ — The Global AI in Clinical Trials Market was valued at USD 2 Billion in 2025 and is projected to grow at a 15.5% CAGR from 2026 to 2034, reaching USD 7.32 Billion by 2034, according to Maximize Market Research.

Global AI in Clinical Trials Market

The Global AI in Clinical Trials Market Report 2026 provides a detailed assessment of market trends, clinical research activity, AI adoption, patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, trial-phase applications, end-user demand, competitive developments, and market forecasts through 2034. The market is segmented by Trial Phase, Technology, Application, End-Users, and Region, covering Phase I, Phase II, and Phase III trials; machine learning, natural language processing, and deep learning; and applications including patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

The market is expanding as pharmaceutical and biotechnology companies increasingly use AI to improve the speed and efficiency of clinical research. AI tools are being applied to patient screening, cohort selection, trial design, large-scale data analysis, safety evaluation, and treatment optimization. By analyzing complex patient datasets, AI can help researchers identify suitable trial participants, detect patterns more quickly, and support more targeted clinical decision-making.

Growing use of machine learning, deep learning, AI-driven patient monitoring, real-world evidence, decentralized trials, and AI-enabled drug discovery is creating new opportunities across the clinical research ecosystem. Pharmaceutical companies, CROs, hospitals, and research institutes are adopting AI to streamline workflows, improve patient recruitment, strengthen data quality, and reduce delays in drug development. These developments are expected to support the AI in Clinical Trials Market as it grows from USD 2 Billion in 2025 to USD 7.32 Billion by 2034 at a CAGR of 15.5%.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market gains momentum as pharmaceutical companies, CROs, and research institutions turn to AI for faster patient recruitment, smarter data analysis, improved safety monitoring, personalized medicine, and more efficient drug development, says Maximize Market Research.

Global AI in Clinical Trials Market Size & Forecast

Parameter

Value

Market Size (Base Year 2025)

USD 2 Billion

Forecast Market Size (2034)

USD 7.32 Billion

CAGR (2026-2034)

15.5 %

Base Year

2025

Forecast Period

2026-2034

Historical Period

2020-2025

Global AI in Clinical Trials Market Trends & Insights

North America leads the Global AI in Clinical Trials Market, supported by strong healthcare infrastructure, a mature pharmaceutical industry, significant investment in AI research, and increasing collaboration between pharmaceutical and technology companies. The United States remains the key regional market, while Europe is also seeing rapid adoption across the UK, Germany, and France.AI adoption is reshaping patient recruitment and clinical trial operations by helping researchers identify suitable participants, analyze large patient datasets, improve cohort selection, and support trial design. These capabilities are helping reduce delays and improve the efficiency of clinical research.Machine learning, natural language processing, and deep learning are becoming central technologies across the AI in Clinical Trials Market. Their use is expanding in patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine across Phase I, Phase II, and Phase III trials.Pharmaceutical and biotechnology companies remain major adopters of AI in clinical research, using the technology to support drug discovery, trial execution, data analysis, and post-market surveillance. CROs, hospitals, research institutes, and government agencies are also increasing adoption as AI becomes more embedded in the clinical research ecosystem.Decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery are emerging as important market trends. Growing use of AI in diagnostics, treatment optimization, patient stratification, and personalized medicine is expected to create new opportunities as the Global AI in Clinical Trials Market advances toward 2034.

Faster Patient Recruitment and Data Analysis Drive Market Growth

The AI in Clinical Trials Market is gaining momentum as pharmaceutical companies, biotechnology firms, CROs, and research organizations look for faster and more efficient ways to manage clinical studies. AI is increasingly being used for patient screening, cohort selection, trial design, data analysis, and recruitment, helping researchers identify suitable participants and process large volumes of clinical information more quickly. These capabilities are improving trial efficiency while supporting faster drug development and better use of research resources.

Data Privacy, Regulatory Compliance, and Data Quality Restrain Adoption

Despite its potential, AI adoption in clinical trials faces important barriers. Data privacy concerns, regulatory compliance, data quality issues, and the need for specialized AI expertise can slow implementation across clinical research organizations. Because clinical trials handle sensitive patient information and operate under strict regulatory requirements, companies must ensure that AI systems are reliable, transparent, and supported by high-quality data before they can be widely integrated into trial workflows.

Decentralized Trials and AI-Driven Drug Discovery Create New Opportunities

The growing use of decentralized clinical trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery is opening new opportunities across the market. Machine learning, deep learning, and natural language processing are being applied to patient recruitment, safety monitoring, personalized medicine, and drug discovery. As AI becomes more deeply embedded in clinical research, companies have greater scope to improve trial design, identify treatment-responsive patient groups, and accelerate development of new therapies.

AI Expertise, Trust, and Reliable Clinical Data Remain Key Challenges

A major challenge for the AI in Clinical Trials Market is ensuring that AI-generated insights are supported by accurate, high-quality clinical data and can be used responsibly in regulated research environments. Organizations also need the right technical expertise to apply AI across trial phases and therapeutic areas. As AI adoption expands, maintaining data integrity, regulatory compliance, patient privacy, and confidence in AI-supported decision-making will remain central to long-term market development.

Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/request-sample/222597/ 

Global AI in Clinical Trials Market Segmentation

The Global AI in Clinical Trials Market is segmented by Trial Phase, Technology, Application, End-Users, and Region. The market covers AI adoption across Phase I, Phase II, and Phase III clinical trials, with technologies such as machine learning, natural language processing, and deep learning supporting patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, research institutes, CROs, hospitals, and other end-users are increasingly integrating AI into clinical research workflows.

Segmentation

Sub-Segments

By Trial Phase

Phase I; Phase II; Phase III

By Technology

Machine Learning; Natural Language Processing; Deep Learning; Unspecified

By Application

Patient Recruitment; Data Analysis; Safety Monitoring; Drug Discovery; Personalized Medicine

By End-Users

Pharmaceutical Companies; Research Institutes; CRO’s; Hospitals; Others

By Region

North America; Europe; Asia Pacific; Middle East & Africa; South America

North America Leads the AI in Clinical Trials Market as Asia Pacific Gains Ground

North America leads the Global AI in Clinical Trials Market, supported by advanced healthcare infrastructure, a well-established pharmaceutical industry, strong investment in AI research, and growing collaboration between drug developers and technology companies. The United States remains the key market as AI is increasingly used for patient recruitment, data analysis, safety monitoring, drug discovery, and personalized medicine.

Europe is also seeing steady adoption of AI in clinical research, particularly across the UK, Germany, and France. Strong pharmaceutical capabilities, established regulatory systems, government support for healthcare AI, and cross-border research partnerships are helping expand the use of machine learning and digital technologies in clinical trials.

Asia Pacific is emerging as an important market, led by China, India, and Japan. Large patient populations, expanding pharmaceutical sectors, and growing interest in more efficient and affordable clinical research are encouraging wider adoption of AI. Japan’s advanced technology ecosystem is also creating opportunities for AI-driven healthcare and clinical trial applications.

South America and the Middle East & Africa remain developing markets for AI in Clinical Trials. Expanding pharmaceutical activity, improving healthcare infrastructure, evolving regulatory frameworks, and partnerships with international research and pharmaceutical organizations are supporting gradual adoption across these regions.

Leading Companies Expand the AI in Clinical Trials Market

Euretos, Biosymetrics, Unlearn.AI, Exscientia, AiCure, Antidote Technologies, Deep 6 AI, Innoplexus, IQVIA, Medidata, Mendel.ai, Phesi, Saama Technologies, Signant Health, Trials.ai, and other participants are active across the AI in Clinical Trials Market. These companies are developing solutions for patient recruitment, clinical data analysis, trial optimization, safety monitoring, and AI-supported drug development.

Global AI in Clinical Trials Market Competitive Landscape

Competition in the Global AI in Clinical Trials Market is becoming more technology-driven as companies focus on machine learning, deep learning, natural language processing, AI-powered patient recruitment, predictive analytics, and personalized medicine. Partnerships between pharmaceutical companies, research institutions, and AI technology providers are also becoming increasingly important in accelerating clinical research.

The market is also being shaped by decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enhanced drug discovery. Companies that can improve trial efficiency, shorten recruitment timelines, strengthen data analysis, and support better treatment decisions are likely to gain greater relevance as AI adoption expands across clinical research through 2034.

Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) https://www.maximizemarketresearch.com/checkout/222597/ 

Key Players of the AI in Clinical Trials Market

EuretosBiosymetricUnlearn.AI,Inc.ExscientiaIMB CorporationAiCureAntidote TechnologiesDeep 6 AIInnoplexusIQVIAMedian TechnologiesMedidataMendel.aiPhesiSaama TechnologiesSignant HealthTrials.ai

Frequently Asked Questions and Answers about AI in Clinical Trials Market

1. How AI can improve clinical trials?
Ans: AI can improve clinical trials by expediting patient recruitment, enhancing data analysis accuracy, personalizing treatment plans, and optimizing trial designs.

2. What are the challenges associated with the integration of AI in clinical trials?
Ans: Challenges associated with integrating AI in clinical trials include data privacy concerns, regulatory compliance, data quality, and the need for AI expertise.

3. What is the role of AI in electronic health records of clinical trials data?
Ans: AI plays a role in electronic health records of clinical trials data by facilitating data management, analysis, and insights for more efficient and informed decision-making.

4. What are the upcoming trends in AI in clinical trial market?
Ans: Upcoming trends in the AI in clinical trial market include decentralized trials, AI-driven patient monitoring, real-world evidence utilization, and AI-enhanced drug discovery.

5. Which region captures the largest share in the AI in clinical trials market?
Ans: North America captures the largest share in the AI in clinical trials market, driven by its robust healthcare infrastructure and significant investments in AI research.

Access Full Summary: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/ 

Analyst Perspective

Analysts note that the Global AI in Clinical Trials Market is being driven by the growing use of AI to improve patient recruitment, clinical data analysis, safety monitoring, drug discovery, and personalized medicine. Pharmaceutical companies, CROs, hospitals, and research institutes are increasingly adopting machine learning, deep learning, and other AI tools to make clinical trials faster and more efficient. Data privacy, regulatory compliance, data quality, and the need for specialized AI expertise remain important challenges, while decentralized trials, AI-driven patient monitoring, real-world evidence, and AI-enabled drug discovery are expected to create new opportunities through 2034.

Related Reports:

Clinical Trial Management Systems Market by Type, Component, Delivery Mode, End User, and Region – Global Forecast to 2034

Healthcare Artificial Intelligence Market by Component, Application, End-User, and Region – Global Forecast to 2034

Clinical Trial Imaging Market by Product and Service, Modality, Application, End Users, and Region – Global Forecast to 2034

Healthcare Analytics Market by Type, Component, Delivery Mode, Application, End-User, and Region – Global Forecast to 2034

Healthcare Big Data Analytics Market by Type, Application, Component, Deployment Model, End User, and Region – Global Forecast to 2034

About Maximize Market Research – Global AI in Clinical Trials Market

Maximize Market Research is a global market research and business consulting firm providing data-driven insights across Healthcare, Pharmaceuticals, Biotechnology, Life Sciences, Clinical Research, and Artificial Intelligence, including the Global AI in Clinical Trials Market. Its research helps businesses understand market dynamics, technology adoption, regulatory developments, competitive activity, and emerging opportunities across patient recruitment, data analysis, safety monitoring, drug discovery, personalized medicine, and AI-enabled clinical research.

Expertise in AI in Clinical Trials & Healthcare Research

Maximize Market Research provides insights across Healthcare, clinical trials, pharmaceutical R&D, biotechnology, and AI-driven medical technologies. Its research covers machine learning, natural language processing, deep learning, AI-powered patient recruitment, clinical data analysis, safety monitoring, drug discovery, personalized medicine, decentralized trials, real-world evidence, and AI-based patient monitoring. The research also evaluates adoption trends across pharmaceutical companies, CROs, hospitals, and research institutes, along with regional and competitive developments shaping the AI in Clinical Trials Market.

Contact:
Lumawant Godage
MAXIMIZE MARKET RESEARCH PVT. LTD.
+91 96073 65656
Email: sales@maximizemarketresearch.com
Content Source: https://www.maximizemarketresearch.com/market-report/ai-in-clinical-trials-market/222597/
Visit Our Web Site: https://www.maximizemarketresearch.com/ 
LinkedIn.com: https://www.linkedin.com/company/maxmize-market-research-pvt-ltd/
Instagram: https://www.instagram.com/maximizemarketresearch/
Facebook: https://www.facebook.com/maximizemarketresearch/ 
X (Twitter): https://x.com/MMRAnalytics

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/ai-in-clinical-trials-market-to-reach-usd-7-32-billion-by-2034-as-ai-reshapes-patient-recruitment-data-analysis-and-drug-development-says-maximize-market-research-302890253.html

Continue Reading

Trending